JERUSALEM, Feb. 29,
2024 /PRNewswire/ -- Scinai Immunotherapeutics
Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on
developing inflammation and immunology (I&I) biological
products and providing CDMO services through its Scinai Bioservices
business unit, today announced that it will be attending the MIXiii
International Life Science and Health-tech Conference, taking place
March 5 and 6 in Jerusalem.
Several members of Scinai's leadership team will be available
for discussions with:
- Prospective clients of the company's end-to-end biologics
CDMO service
- Potential pharmaceutical industry partners to
advance Scinai's innovative NanoAb pipeline
- Investors interested in SCNI's value proposition
All interested parties are encouraged to email Scinai at
bd@scinai.com to schedule a one-to-one meeting.
Scinai will also be participating in the Bio Europe Spring conference in Barcelona, Spain on March 18 to 20. Details are listed on Scinai's
website at www.scinai.com/events.
Scinai's CEO, Amir
Reichman, provided an overview of Scinai's activities
and plans on a recent episode of the Xtalks Life Science Podcast,
available at
https://xtalks.com/biologics-development-in-immunology-and-inflammation-featuring-amir-reichman-ceo-of-scinai-immunotherapeutics-xtalks-life-science-podcast-ep-147/.
About Scinai Immunotherapeutics
Scinai
Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical
company with two complementary business units, one focused on
in-house development of inflammation and immunology (I&I)
biological therapeutic products beginning with an innovative,
de-risked pipeline of nanosized VHH antibodies (NanoAbs) targeting
diseases with large unmet medical needs, and the other a boutique
CDMO providing biological drug development, analytical methods
development, clinical GMP manufacturing, and pre-clinical and
clinical trial design and execution services to early stage biotech
companies. Company website: www.scinai.com.
Company Contact
Investor Relations | +972 8 930 2529 |
ir@scinai.com
Forward-Looking Statements
This press release
contains forward-looking statements within the meaning of the
Private Litigation Reform Act of 1995. Words such as "expect,"
"believe," "intend," "plan," "continue," "may," "will,"
"anticipate," and similar expressions are intended to identify
forward-looking statements. All statements, other than statements
of historical facts, included in this press release regarding
strategy, future operations, future financial position, future
revenue, projected expenses, prospects, plans and objectives of
management are forward-looking statements. Examples of such
statements include, but are not limited to, the potential of
Scinai's NanoAb pipeline, and the expansion of the
CDMO business and the timing of human clinical trials. These
forward-looking statements reflect management's current views with
respect to certain current and future events and are subject to
various risks, uncertainties and assumptions that could cause the
results to differ materially from those expected by the management
of Scinai Immunotherapeutics Ltd. Risks and
uncertainties include, but are not limited to, the risk of delay
in, or Scinai's inability to conduct, its research and development
activities, including the contemplated in-vivo studies
and a clinical trial; the risk that Scinai will not remain
listed on Nasdaq; the risk that Scinai will not be successful in
expanding its CDMO business or in-license other NanoAbs; the
risk that Scinai may not be able to secure additional
capital on attractive terms, if at all; the risk that the
therapeutic and commercial potential of NanoAbs will not be met or
that Scinai will not be successful in bringing the NanoAbs towards
commercialization; the risk of a delay in the preclinical and
clinical trials data for NanoAbs, if any; the risk that our
business strategy may not be successful; the risk that the European
Investment Bank (EIB) may accelerate the financial facility under
its finance contract with Scinai; Scinai's ability to acquire
rights to additional product opportunities; Scinai's ability to
enter into collaborations on terms acceptable to Scinai or at all;
timing of receipt of regulatory approval of Scinai's manufacturing
facility in Jerusalem, if at all
or when required; the risk that the manufacturing facility will not
be able to be used for a wide variety of applications and other
vaccine and treatment technologies; and the risk that drug
development involves a lengthy and expensive process with uncertain
outcomes. More detailed information about the risks and
uncertainties affecting the Company is contained under the heading
"Risk Factors" in the Company's Annual Report on Form 10-K filed
with the Securities and Exchange Commission ("SEC") on April 17, 2023, and the Company's subsequent
filings with the SEC. Scinai undertakes no obligation to revise or
update any forward-looking statement for any reason.
Logo:
https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/scinai-to-showcase-its-cgmp-biologics-cdmo-and-innovative-nanoab-pipeline-at-mixiii-2024-302075809.html
SOURCE Scinai Immunotherapeutics Ltd.